Norwegian pharma company Navamedic and German pharma company Evolsin Medical, have signed an exclusive distribution agreement for Germany. The first product to be launched in Germany will be Navamedic’s extra effective antiperspirant product Dermix® Absolut Torr® with a private label tailored for the German market: Evolsin® 7-Tage Antitranspirant

“We are excited about the collaboration with Evolsin and believe that Absolut Torr will have a good potential in Germany. In addition, the collaboration opens for additional products for the German market.” says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.

“Evolsin® 7-Tage Antitranspirant fits well into our established skin care business where we also have a strong digital presence.” Daniel Dilges, Chief Executive Officer of Evolsin, adds.

Dermix Absolut Torr is classified as a cosmetic product, developed and manufactured in Sweden. It comes in three different presentations, roll-on, dab-on and wipes. Absolut Torr has so far been launched in the Nordics, the Middle East and Balkans. It is also sold under the brand Dermix Absolut Dry®. With its 84 million inhabitants, Germany will be the single largest market to launch so far. The launch in the Germany is expected early 2026.